Personalised medicine: Not just in our genes

BMJ (Online)

Volumn 344, Issue 7859, 2012, Pages

  Kitsios, Georgios D ^a,b   Kent, David M ^a,c  

^a TUFTS MEDICAL CENTER   (United States)

^b LAHEY HOSPITAL AND MEDICAL CENTER   (United States)

^c TUFTS UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ATORVASTATIN; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CARDIOVASCULAR AGENT; CLOPIDOGREL; DABIGATRAN; DIURETIC AGENT; HYDRALAZINE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; ISOSORBIDE; PLACEBO; PRASUGREL; PROPAFENONE; RIVAROXABAN; TICAGRELOR; WARFARIN; XIMELAGATRAN;

ADRB1 GENE; APOC1 GENE; APOE GENE; ARTICLE; CETP GENE; CLINICAL PRACTICE; CLMN GENE; CYP2C18 GENE; CYP2C19 GENE; CYP2C9 GENE; CYP2D6 GENE; CYP4F2 GENE; DRUG EFFICACY; DRUG RESPONSE; FORECASTING; FRS2 GENE; GENE; GENETIC ASSOCIATION; GENETIC RISK; GENETIC VARIABILITY; GENOTYPE; HEART ATRIUM FIBRILLATION; HERITABILITY; HLA DRB1 GENE; HUMAN; ISCHEMIC HEART DISEASE; ITGB3 GENE; LDLR GENE; LYZ GENE; NAT1 GENE; NAT2 GENE; PERSONALIZED MEDICINE; PHARMACOGENOMICS; PRACTICE GUIDELINE; PREDICTION; PRIORITY JOURNAL; RYR2 GENE; SINGLE NUCLEOTIDE POLYMORPHISM; SLCO1B1 GENE; VKORC1 GENE; YEATS4 GENE;

CARDIOVASCULAR AGENTS; CARDIOVASCULAR DISEASES; HUMANS; INDIVIDUALIZED MEDICINE; PHARMACOGENETICS; POLYMORPHISM, SINGLE NUCLEOTIDE; REVIEW LITERATURE AS TOPIC;

EID: 84861870849     PISSN: 17561833     EISSN: None     Source Type: Journal    
DOI: 10.1136/bmj.e2161     Document Type: Article

References (34)

1. Hindorff LA, Sethupathy P, Junkins HA, Ramos EM, Mehta JP, Collins FS, et al. Potential etiologic and functional implications of genome-wide association loci for human diseases and traits. Proc Natl Acad Sci USA 2009;106:9362-7.
2. Janssens AC, van Duijn CM. An epidemiological perspective on the future of direct-to-consumer personal genome testing. Invest Genet 2010;1:10.
3. Goldstein DB. Common genetic variation and human traits. N Engl J Med 2009;360:1696-8.
4. Ioannidis JP. Prediction of cardiovascular disease outcomes and established cardiovascular risk factors by genome-wide association markers. Circ Cardiovasc Genet 2009;2:7-15.
5. Manolio TA, Collins FS, Cox NJ, Goldstein DB, Hindorff LA, Hunter DJ, et al. Finding the missing heritability of complex diseases. Nature 2009;461:747-53.
6. Imai K, Kricka LJ, Fortina P. Concordance study of 3 direct-to-consumer genetic-testing services. Clin Chem 2011;57:518-21.
7. Becquemont L, Alfirevic A, Amstutz U, Brauch H, Jacqz-Aigrain E, Laurent-Puig P, et al. Practical recommendations for pharmacogenomics-based prescription: 2010 ESF-UB Conference on pharmacogenetics and pharmacogenomics. Pharmacogenomics 2011;12:113-24.
8. Swen JJ, Huizinga TW, Gelderblom H, de Vries EG, Assendelft WJ, Kirchheiner J, et al. Translating pharmacogenomics: challenges on the road to the clinic. PLoS Med 2007;4:e209.
9. Holmes MV, Shah T, Vickery C, Smeeth L, Hingorani AD, Casas JP. Fulfilling the promise of personalized medicine? Systematic review and field synopsis of pharmacogenetic studies. PLoS One 2009;4:e7960.
10. US Food and Drug Administration. Table of pharmacogenomic biomarkers in drug labels. 2011. www.fda.gov/drugs/scienceresearch/researchareas/ pharmacogenetics/ucm083378. htm.
11. Sofi F, Marcucci R, Gori AM, Giusti B, Abbate R, Gensini GF. Clopidogrel non-responsiveness and risk of cardiovascular morbidity. An updated meta-analysis. Thromb Haemost 2010;103:841-8.
12. Aradi D, Komocsi A, Vorobcsuk A, Rideg O, Tokes-Fuzesi M, Magyarlaki T, et al. Prognostic significance of high on-clopidogrel platelet reactivity after percutaneous coronary intervention: systematic review and meta-analysis. Am Heart J 2010;160:543-51.
13. Snoep JD, Hovens MM, Eikenboom JC, van der Bom JG, Jukema JW, Huisman MV. Clopidogrel nonresponsiveness in patients undergoing percutaneous coronary intervention with stenting: a systematic review and meta-analysis. Am Heart J 2007;154:221-31. (Pubitemid 47069129)
14. Combescure C, Fontana P, Mallouk N, Berdague P, Labruyere C, Barazer I, et al. Clinical implications of clopidogrel non-response in cardiovascular patients: a systematic review and meta-analysis. J Thromb Haemost 2010;8:923-33.
15. Dahabreh IJ, Terasawa T, Castaldi PJ, Trikalinos TA. Systematic review: anti-epidermal growth factor receptor treatment effect modification by KRAS mutations in advanced colorectal cancer. Ann Intern Med 2011;154:37-49.
16. Holmes MV, Perel P, Shah T, Hingorani AD, Casas JP. CYP2C19 genotype, clopidogrel metabolism, platelet function, and cardiovascular events: a systematic review and meta-analysis. JAMA 2011;306:2704-14.
17. Nissen SE. Pharmacogenomics and clopidogrel: irrational exuberance? JAMA 2011;306:2727-8.
18. Holmes DR Jr, Dehmer GJ, Kaul S, Leifer D, O'Gara PT, Stein CM. ACCF/AHA clopidogrel clinical alert: approaches to the FDA "boxed warning": a report of the American College of Cardiology Foundation Task Force on clinical expert consensus documents and the American Heart Association endorsed by the Society for Cardiovascular Angiography and Interventions and the Society of Thoracic Surgeons. J Am Coll Cardiol 2010;56:321-41.
19. Institute for Clinical Systems Improvement. Diagnosis and treatment of chest pain and acute coronary syndrome (ASC) guidelines. ICSI, 2010.
20. Kangelaris KN, Bent S, Nussbaum RL, Garcia DA, Tice JA. Genetic testing before anticoagulation? A systematic review of pharmacogenetic dosing of warfarin. J Gen Intern Med 2009;24:656-64.
21. Ansell J, Hirsh J, Hylek E, Jacobson A, Crowther M, Palareti G. Pharmacology and management of the vitamin K antagonists: American College of Chest Physicians evidence-based clinical practice guidelines (8th edition). Chest 2008;133:160-98S.
22. Medical Services Commission. Warfarin therapy - management during invasive procedures and surgery. 2011. www.bcguidelines.ca/guideline-warfarin- invasive.html.
23. Institute for Clinical Systems Improvement. Antithrombotic therapy supplement (guideline). 2011. www.icsi.org/guidelines-and-more/gl-os-prot/ cardiovascular/antithrombotic- therapy-supplement-guideline-14045/ antithrombotic-therapy-supplement-guideline. html.
24. Flockhart DA, O'Kane D, Williams MS, Watson MS, Flockhart DA, Gage B, et al. Pharmacogenetic testing of CYP2C9 and VKORC1 alleles for warfarin. Genet Med 2008;10:139-50. (Pubitemid 351271726)
25. Barber MJ, Mangravite LM, Hyde CL, Chasman DI, Smith JD, McCarty CA, et al. Genome-wide association of lipid-lowering response to statins in combined study populations. PLoS One 2010;5:e9763.
26. Veenstra DL, Higashi MK, Phillips KA. Assessing the cost-effectiveness of pharmacogenomics. AAPS Pharm Sci 2000;2:E29.
27. Rothwell PM. Can overall results of clinical trials be applied to all patients? Lancet 1995;345:1616-9.
28. Kravitz RL, Duan N, Braslow J. Evidence-based medicine, heterogeneity of treatment effects, and the trouble with averages. Milbank Q 2004;82:661-87. (Pubitemid 40143102)
29. Kent DM, Hayward RA. Limitations of applying summary results of clinical trials to individual patients: the need for risk stratification. JAMA 2007;298:1209-12. (Pubitemid 47403108)
30. Kent DM, Rothwell PM, Ioannidis JP, Altman DG, Hayward RA. Assessing and reporting heterogeneity in treatment effects in clinical trials: a proposal. Trials 2010;11:85.
31. Rothwell PM, Warlow CP. Prediction of benefit from carotid endarterectomy in individual patients: a risk-modelling study. European Carotid Surgery Trialists' Collaborative Group. Lancet 1999;353:2105-10. (Pubitemid 29278479)
32. Kent DM, Hayward RA, Griffith JL, Vijan S, Beshansky JR, Califf RM, et al. An independently derived and validated predictive model for selecting patients with myocardial infarction who are likely to benefit from tissue plasminogen activator compared with streptokinase. Am J Med 2002;113:104-11. (Pubitemid 34804746)
33. Hayward RA, Kent DM, Vijan S, Hofer TP. Multivariable risk prediction can greatly enhance the statistical power of clinical trial subgroup analysis. BMC Med Res Methodol 2006;6:18.
34. Hayward RA, Kent DM, Vijan S, Hofer TP. Reporting clinical trial results to inform providers, payers, and consumers. Health Aff (Millwood) 2005;24:1571-81.